(NASDAQ: CRSP) Crispr Therapeutics Ag's forecast annual revenue growth rate of 145.62% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.71%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Crispr Therapeutics Ag's revenue in 2025 is $38,050,000.On average, 11 Wall Street analysts forecast CRSP's revenue for 2025 to be $3,420,463,508, with the lowest CRSP revenue forecast at $318,326,481, and the highest CRSP revenue forecast at $13,005,910,489. On average, 11 Wall Street analysts forecast CRSP's revenue for 2026 to be $21,917,596,736, with the lowest CRSP revenue forecast at $318,326,481, and the highest CRSP revenue forecast at $134,579,340,913.
In 2027, CRSP is forecast to generate $55,260,931,312 in revenue, with the lowest revenue forecast at $9,040,472,046 and the highest revenue forecast at $206,111,848,603.